|Friday, April 3, 2020|
7:30AM - Atherosclerotic Cardiovascular Disease, Heart Failure, and SGLT2 Inhibitors
Caribe Royale • Caribbean Ballroom V & VI • 8101 World Center Drive, Orlando, Florida
Atherosclerotic Cardiovascular Disease, Heart Failure, and SGLT2 Inhibitors: Insights into Implementing Evidence Based Treatment Strategies
In this symposium, experts in HF and comorbid diabetes will provide cardiovascular nurses with up-to-date evidence with SGLT2 inhibitors on ASCVD risk reduction, and prevention and treatment of HF. Tips for cardiovascular nurses on how to use SGLT2 inhibitors safely and effectively will be presented, with a case presentation illustrating best practices and describing supportive evidence.
For registration information, click here: https://pcna.net/professional-development/annual-symposium/registration/
|Wednesday, April 22, 2020|
6:00PM - Reducing Cardiovascular and Renal Risk in Your Patients with Type 2 Diabetes
JW Marriott Los Angeles L.A. LIVE • Platinum B-C Ballroom • 900 W Olympic Blvd., Los Angeles, California
Reducing Cardiovascular and Renal Risk in Your Patients with Type 2 Diabetes:
Interpreting the Evidence with SGLT2 Inhibitors
In this educational initiative, to take place at the ACP 2020 annual meeting, experts from primary care, cardiology, and nephrology will interpret the latest findings, elaborate current recommendations, and describe best practices for the use of SGLT2 inhibitors.
Click here to pre-register: https://www.symposiareg.com/22003/